RxDoctor Payments DataLook up a doctor →

Joseph Diaz, MD

Allergy & Immunology · San Antonio, TXNPI 1417948241

Payments from drug & device makers

$1,786,216in general payments, 2019–2025

Across 2,279 payments — averaging $783.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$966K
  • Sanofi US Services Inc.$202K
  • Genentech USA, Inc.$123K
  • Novartis$88K
  • Amgen$69K
  • Teva Pharmaceuticals USA, Inc.$59K
  • plus $279K from 37 others

What the payments were for

  • Consulting fees$101,6979%
  • Speaking & faculty fees$849,39475%
  • Travel & lodging$131,70012%
  • Food & beverage$48,3114%
  • Education$8660%
  • Other$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,786,216 in reported general payments places this provider in the 95th percentile of 336 allergy & immunology providers in Texas.

See all allergy & immunology providers in Texas

Medicare billing

Part B allowed, 2024
$112,418
Medicare patients
127
Services billed
3,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FirazyrIcatibant Acetate11$754,723
TakhzyroLanadelumab-Flyo11$517,209
Dupixent SyringeDupilumab37$140,818
NucalaMepolizumab14$59,950
XolairOmalizumab11$32,579
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$29,446
Breo ElliptaFluticasone/Vilanterol37$17,899
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$13,547
Spiriva RespimatTiotropium Bromide13$10,055
Epinephrine33$6,223
Qvar RedihalerBeclomethasone Dipropionate18$4,893
Azelastine-FluticasoneAzelastine/Fluticasone21$3,927
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$1,471
Fluticasone Propionate103$1,355
Albuterol Sulfate HfaAlbuterol Sulfate56$1,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Firazyr, Takhzyro$38,470$1,271,93322 claims
GSKNucala, Trelegy Ellipta, Breo Ellipta$10,617$107,29683 claims
Genentech, Inc.Xolair$49,737$32,57911 claims
AstraZenecaBreztri Aerosphere$965,501$13,54713 claims
Boehringer IngelheimSpiriva Respimat$345$10,05513 claims
Hikma Pharmaceuticals USAEpinephrine$13$6,22333 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$59,328$4,89318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 336 allergy & immunology providers in Texas.

Other allergy & immunology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →